# Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

> **NCT04313322** · PHASE1 · UNKNOWN · sponsor: **Stem Cells Arabia** · enrollment: 5 (estimated)

## Conditions studied

- Use of Stem Cells for COVID-19 Treatment

## Interventions

- **BIOLOGICAL:** WJ-MSCs

## Key facts

- **NCT ID:** NCT04313322
- **Lead sponsor:** Stem Cells Arabia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-16
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313322, "Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04313322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*